Effexor Capsule, Extended Release
Product Images NDC 58151-126

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Effexor (NDC 58151-126). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Viatris Specialty Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Effexor Xr Extended-release Capsules 37.5 mg Bottle Label (Image 01)

Effexor Xr Extended-release Capsules 37.5 mg Bottle Label (Image 01)
Effexor XR 37.5 mg extended-release capsules packaging label showing the product name, active ingredient venlafaxine HCl, dosage strength 37.5 mg, quantity of 30 capsules, and labeler Viatris Specialty LLC. The label includes storage instructions, a barcode, and regulatory text.*
FDA Label Image

Effexor Xr Extended-release Capsules 75 mg Bottle Label (Image 02)

Effexor Xr Extended-release Capsules 75 mg Bottle Label (Image 02)
Label for Effexor XR 75 mg extended-release capsules containing venlafaxine HCl. The label indicates a package of 30 capsules, distributed by Viatris Specialty LLC, Morgantown, WV, made in Ireland. It includes storage instructions for controlled room temperature (20° to 25°C) and notes that each capsule contains venlafaxine HCl equivalent to 75 mg venlafaxine.*
FDA Label Image

Effexor Xr Extended-release Capsules 150 mg Bottle Label (Image 03)

Effexor Xr Extended-release Capsules 150 mg Bottle Label (Image 03)
Label for Effexor XR 150 mg extended-release capsules, containing venlafaxine HCl. The label shows packaging for 30 capsules, distributed by Viatris Specialty LLC, Morgantown, WV, made in Ireland. It includes storage instructions at controlled room temperature and a note to always dispense with the medication guide.*
FDA Label Image

Venlafaxine Hydrochloride Structural Formula (Image 04)

Venlafaxine Hydrochloride Structural Formula (Image 04)
Chemical structure of venlafaxine hydrochloride displayed as a 2D molecular diagram, showing the arrangement of atoms and functional groups in the compound.*
FDA Label Image

Figure 1: Pharmacokinetics Of Venlafaxine And Active Metabolite O-desmethylvenlafaxine (odv) In Special Populations (Image 05)

Figure 1: Pharmacokinetics Of Venlafaxine And Active Metabolite O-desmethylvenlafaxine (odv) In Special Populations (Image 05)
Chart depicting fold change and 90% confidence intervals for venlafaxine and its metabolite ODV pharmacokinetics (Cmax and AUC) across various special populations (hepatic impairment, renal impairment, CYP2D6 polymorphism, age, and gender). The X-axis shows change relative to reference values, illustrating variability in drug exposure.*
FDA Label Image

Figure 2: Effect Of Other Drugs On The Pharmacokinetics Of Venlafaxine And Active Metabolite O Desmethylvenlafaxine (odv) (Image 06)

Figure 2: Effect Of Other Drugs On The Pharmacokinetics Of Venlafaxine And Active Metabolite O Desmethylvenlafaxine (odv) (Image 06)
A scatter plot chart showing the fold change and 90% confidence intervals for pharmacokinetic parameters (Cmax, AUC, ODV) of venlafaxine when interacting with various drugs, including Ethanol, Diazepam, Cimetidine, Ketoconazole (in CYP2D6 EM's and PM's), Indinavir, Metoprolol, Imipramine, and Lithium. The x-axis represents change relative to the reference value, ranging from 0 to 3.*
FDA Label Image

Figure 3: Effect Of Venlafaxine On The Pharmacokinetics Of Interacting Drugs And Their Active Metabolites (Image 07)

Figure 3: Effect Of Venlafaxine On The Pharmacokinetics Of Interacting Drugs And Their Active Metabolites (Image 07)
A chart depicting the fold change and 90% confidence interval in pharmacokinetic parameters (Cmax and AUC) for various analytes when interacting with different drugs. The x-axis represents change relative to the reference value, ranging from 0 to 3. The chart compares multiple drugs, including ethanol, diazepam, alprazolam, indinavir, metoprolol, risperidone, imipramine, haloperidol, caffeine, tolbutamide, and lithium, showing the impact on Cmax and AUC values for their respective analytes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.